New Century Investment Management Inc Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : New Century Investment Management Inc reduced its stake in Gilead Sciences by 12.28% during the most recent quarter end. The investment management company now holds a total of 50,991 shares of Gilead Sciences which is valued at $4,413,271 after selling 7,137 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.Gilead Sciences makes up approximately 2.27% of New Century Investment Management Inc’s portfolio.

Other Hedge Funds, Including , Delta Asset Managementtn boosted its stake in GILD in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 102 shares of Gilead Sciences which is valued at $8,828.Pennsylvania Trust Co boosted its stake in GILD in the latest quarter, The investment management firm added 905 additional shares and now holds a total of 104,761 shares of Gilead Sciences which is valued at $9,078,588. Gilead Sciences makes up approx 0.72% of Pennsylvania Trust Co’s portfolio.Simplex Trading boosted its stake in GILD in the latest quarter, The investment management firm added 27,576 additional shares and now holds a total of 43,854 shares of Gilead Sciences which is valued at $3,800,388. Gilead Sciences makes up approx 0.48% of Simplex Trading’s portfolio.Mai Capital Management reduced its stake in GILD by selling 4,072 shares or 14.71% in the most recent quarter. The Hedge Fund company now holds 23,613 shares of GILD which is valued at $2,052,678. Gilead Sciences makes up approx 0.16% of Mai Capital Management’s portfolio.Trust Co Of Oklahoma boosted its stake in GILD in the latest quarter, The investment management firm added 435 additional shares and now holds a total of 5,874 shares of Gilead Sciences which is valued at $510,627. Gilead Sciences makes up approx 0.28% of Trust Co Of Oklahoma’s portfolio.

Gilead Sciences opened for trading at $85.46 and hit $87.12 on the upside on Wednesday, eventually ending the session at $86.66, with a gain of 1.43% or 1.22 points. The heightened volatility saw the trading volume jump to 90,55,877 shares. Company has a market cap of $115,416 M.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.